Transcatheter arterial chemoembolization has been shown to improve survival in patients with unresectable hepatocellular carcinoma.
Dr Kwo and colleagues from Indianapolis, USA identified pretreatment factors that predicts increased mortality in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization.
|Mean survival post-transcatheter arterial chemoembolization was 12 months|
|Alimentary Pharmacology & Therapeutics|
The team conducted a retrospective review of all patients who underwent transcatheter arterial chemoembolization for hepatocellular carcinoma from 1999 to 2004.
Patient demographics, etiology of liver disease, laboratory and imaging data regarding tumor characteristics were obtained.
The team of doctors assessed 88 patients who received 1 to 4 sessions of transcatheter arterial chemoembolization.
The doctors found that tumor size was 3 cm, and the mean number of lesions was 2.
Mean model for the end stage liver disease score was 11, and cancer of the liver Italian program score was 1.
The doctors observed that mean survival post-transcatheter arterial chemoembolization was 12 months.
By multivariate analysis, tumor size, hypovascularity, and elevated international normalized ratio were significant risk factors for increased mortality.
Dr Kwo's team concluded, "Transcatheter arterial chemoembolization therapy leads to a mean survival of 12 months in patients not receiving orthotopic liver transplantation."
"Tumor size, hypovascularity on imaging, and elevated international normalized ratio are predictors of increased mortality after transcatheter arterial chemoemboliza therapy for hepatocellular carcinoma."